
Oscar Health (OSCR) Stock Forecast & Price Target
Oscar Health (OSCR) Analyst Ratings
Bulls say
Oscar Health's 2Q25 revenue reached $2.86 billion, showing a strong year-over-year growth of 29%, driven by high retention rates and an increase in special enrollment period (SEP) members, indicating robust demand for its insurance offerings. The company reported a medical loss ratio (MLR) of 91.1%, which, despite being above the consensus estimate, reflects a significant improvement from the previous year's performance and sequentially indicates effective management of healthcare costs relative to premiums. Furthermore, management anticipates increased utilization in 4Q25, suggesting confidence in sustained business momentum and potential for further revenue growth.
Bears say
Oscar Health Inc. reported a significant operating loss of $230.5 million in the second quarter of 2025, which aligns with previous announcements and highlights ongoing financial distress. The company's adjusted EBITDA of negative $199.4 million fell short of market expectations, indicating operational challenges and potential inefficiencies. Additionally, management anticipates a decline in individual membership by year-end, suggesting further erosion of revenue potential and a weakening market position.
This aggregate rating is based on analysts' research of Oscar Health and is not a guaranteed prediction by Public.com or investment advice.
Oscar Health (OSCR) Analyst Forecast & Price Prediction
Start investing in Oscar Health (OSCR)
Order type
Buy in
Order amount
Est. shares
0 shares